Allarity Therapeutics Feed

2021-12-13 23:00:00 Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North 1,74 SEK | -20,91%

2021-12-11 15:35:00 Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North 2,20 SEK | -8,26%

2021-11-24 23:15:00 Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization 2,41 SEK | -3,75%

2021-11-24 21:50:00 Grant of New Warrants and Resolutions on Existing Warrants 2,41 SEK | -3,75%

2021-11-23 08:00:00 Allarity Therapeutics Publishes Interim Report for the Period January – September 2021 2,60 SEK | -7,14%

2021-11-23 00:00:59 Minutes of Extraordinary General Meeting held on 22 November 2021 2,80 SEK | -1,69%

2021-11-11 08:30:00 Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus 2,18 SEK | +18,89%

2021-11-05 22:11:31 NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021 1,83 SEK | +23,57%

2021-11-05 21:48:35 U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq 1,83 SEK | +23,57%

2021-09-23 09:00:00 Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate 1,67 SEK | +3,48%

2021-09-16 10:00:00 Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress 1,80 SEK | +13,25%

2021-09-15 23:55:53 Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3 1,80 SEK | +13,25%

2021-09-14 23:06:29 Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3 1,59 SEK | -0,56%

2021-08-31 21:19:54 MINUTES OF EXTRAORDINARY GENERAL MEETING 2021 1,77 SEK | +0,85%

2021-08-26 08:32:48 Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021 1,92 SEK | -0,05%

2021-08-23 08:45:00 Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq 1,91 SEK | -16,37%

2021-08-23 07:00:00 Allarity Therapeutics Publishes Interim Report for the Period January – June 2021 1,91 SEK | -16,37%

2021-08-19 21:45:00 New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report 2,28 SEK | +29,19%

2021-08-18 08:26:20 Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021 1,90 SEK | -0,52%

2021-08-16 23:18:13 NOTICE OF EXTRAORDINARY GENERAL MEETING 1,91 SEK | -9,82%

2021-08-05 13:00:00 Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus 1,76 SEK | +8,71%

2021-07-26 08:30:00 Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven 0,94 SEK | +0,91%

2021-07-14 17:00:00 Allarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021 0,94 SEK | +6,18%

2021-07-05 20:00:00 Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP® 0,97 SEK | -0,82%

2021-06-24 16:05:48 Last day of trading with Allarity Therapeutics A/S BTU 0,94 SEK | +6,92%

2021-06-14 13:00:00 Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib 0,89 SEK | -2,75%

2021-06-11 00:01:05 Allarity Therapeutics Completes Oversubscribed Rights Issue 0,93 SEK | +4,19%

2021-06-09 11:08:02 Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic 0,90 SEK | -1,54%

2021-05-28 13:45:00 Allarity Therapeutics Publishes Interim Report for the Period January – March 2021 0,94 SEK | -5,05%

2021-05-27 15:21:37 Allarity Therapeutics Publishes Prospectus Supplement 0,99 SEK | +7,61%

2021-05-21 07:21:31 Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics 1,23 SEK | +48,16%

2021-05-21 07:00:00 Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics 1,23 SEK | +48,16%

2021-05-19 08:30:00 Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue 0,82 SEK | -4,53%

2021-05-05 23:11:50 Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue 0,85 SEK | +0,12%

2021-04-29 16:31:01 Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress 0,91 SEK | +3,68%

2021-04-15 21:00:54 MINUTES OF ANNUAL GENERAL MEETING 2021 0,88 SEK | -3,08%

2021-04-02 13:00:00 Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib 0,94 SEK | +8,97%

2021-03-31 23:00:00 Notice of Annual General Meeting 0,86 SEK | -3,33%

2021-03-31 08:30:00 Allarity Therapeutics Publishes its Annual Report for 2020 0,89 SEK | -2,70%

2021-03-23 08:30:00 Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million 0,83 SEK | -7,22%

2021-03-09 13:00:00 Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma 0,99 SEK | +4,18%

2021-03-04 15:00:00 Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer 0,94 SEK | +5,34%

2021-02-24 16:19:57 Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus 1,14 SEK | +79,38%

2021-02-11 13:00:00 Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP 0,73 SEK | -5,81%

2021-01-26 13:00:00 Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus 0,75 SEK | -7,73%

2021-01-22 17:00:00 Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered 0,84 SEK | -0,35%

2020-12-22 13:00:00 Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP 0,86 SEK | -17,78%

2020-12-18 15:21:59 2020 in Review: A Letter from Allarity’s CEO 1,11 SEK | -2,96%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Allarity Therapeutics

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden